Comparison
Epitalon vs Low-Dose Naltrexone
Side-by-side of Epitalon and Low-Dose Naltrexone. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Epitalon
Epitalon peptide (Epithalon, tetrapeptide AEDG): telomerase activation, lifespan extension data, anti-aging trials, dosage, half-life, and safety.
Low-Dose Naltrexone
Low dose naltrexone at 1.5 to 4.5 mg, one-tenth the 50 mg addiction dose. Compounded Rx. Small trials in fibromyalgia, Crohn's, Hashimoto's.
Effects at a glance
Epitalon
- •Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed at the St. Petersburg Institute of Bioregulation
- •Russian clinical literature reports mortality reduction in elderly cohorts and improved melatonin output
- •Reported telomerase activation in human somatic cell culture and lifespan extension in mice and Drosophila
- •Independent Western replication is essentially absent; no FDA-standard RCTs
- •Anecdotal protocols use 5 to 10 mg subcutaneously daily for 10 to 20 day cycles, 2 to 4 times yearly
- •Not currently on the WADA Prohibited List
Low-Dose Naltrexone
- •Off-label use at 1.5 to 4.5 mg, roughly one-tenth the FDA-approved 50 mg addiction-treatment dose
- •Proposed mechanisms include brief opioid receptor blockade triggering rebound endogenous opioid release, plus TLR4 antagonism
- •Compounded prescription only; insurance rarely covers; cash prices 20 to 80 USD per month
- •Younger 2013 reported ~30% pain reduction in fibromyalgia at 4.5 mg in a small crossover trial
- •Smith 2011 reported endoscopic improvement in active Crohn's disease (n=40 placebo-controlled)
- •Vivid dreams affect 20 to 40% in first 2 weeks; manageable by switching to morning dosing
Side-by-side
| Attribute | Epitalon | Low-Dose Naltrexone |
|---|---|---|
| Category | peptide | pharmaceutical |
| Also known as | Epithalon, Ala-Glu-Asp-Gly, AEDG, Epithalamin (precursor extract) | LDN, naltrexone (low dose) |
| Half-life (hr) ↗ | 0.5 | 4 |
| Typical dose (mg) ↗ | 5 | 4.5 |
| Dosing frequency | daily during cycle | once daily, typically at bedtime |
| Routes | subcutaneous, intramuscular, intranasal | oral |
| Onset (hr) | 24 | 1 |
| Peak (hr) | 168 | 1.5 |
| Molecular weight | 390.35 | 341.4 |
| Molecular formula | C14H22N4O9 | C20H23NO4 |
| Mechanism | Synthetic tetrapeptide proposed to interact directly with DNA and chromatin to modulate tissue-specific gene expression. Reported effects include telomerase activation, increased melatonin output from pineal cells, and circadian normalization. | Brief mu-opioid receptor antagonism proposed to trigger compensatory upregulation of endogenous opioids; secondary TLR4 antagonism on microglia and immune cells contributes to anti-inflammatory effect. |
| Legal status | Not FDA approved; registered in Russia under domestic pharmaceutical framework; research-use-only grey market in US/EU | Off-label compounded prescription (naltrexone is FDA approved for opioid and alcohol use disorder at 50 mg) |
| WADA status | unknown | allowed |
| DEA / Rx | Not scheduled (research chemical) | Rx only (not a controlled substance) |
| Pregnancy | Insufficient data; not recommended | Insufficient data; not routinely recommended |
| CAS | 307297-39-8 | 16590-41-3 |
| PubChem CID | 219042 | 5360515 |
| Wikidata | Q5384126 | Q426444 |
Safety profile
Epitalon
Common side effects
- injection-site reactions
- occasional mild headache (rare)
Contraindications
- pregnancy
- lactation
- active malignancy (theoretical telomerase concern)
- concurrent immunosuppression
Interactions
- melatonin: potential additive effect on circadian and pineal output; no controlled data(minor)
Low-Dose Naltrexone
Common side effects
- vivid dreams
- sleep disruption
- headache
- mild GI upset
- fatigue (early)
Contraindications
- concurrent opioid use
- acute hepatitis or liver failure
- opioid dependence
- pregnancy (insufficient data)
Interactions
- opioid analgesics (oxycodone, morphine, codeine): blocks analgesic effect; precipitates withdrawal in dependent users(major)
- tramadol: blocks opioid component of analgesia(major)
- thyroid hormone replacement: may alter dose requirements after immune modulation; monitor TSH(minor)
Which Should You Take?
Low-Dose Naltrexone comes out ahead for most readers on the criteria we weight: 2 catalogued goals, prescription-only, oral dosing, with a Tier-A outcome catalogued. Epitalon is the right call when one of the conditionals below applies.
- → If your priority is healthspan extension, pick Epitalon.
- → If your priority is sleep onset or sleep quality, pick Epitalon.
- → If your priority is immune support, pick Low-Dose Naltrexone.
- → If your priority is pain modulation, pick Low-Dose Naltrexone.
Edge case: If you cannot self-administer injections, Low-Dose Naltrexone is the only oral option in this pair.
Default choice: Low-Dose Naltrexone. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Epitalon only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Epitalon and Low-Dose Naltrexone?
Epitalon and Low-Dose Naltrexone differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Epitalon or Low-Dose Naltrexone?
Epitalon half-life is 0.5 hours; Low-Dose Naltrexone half-life is 4 hours.
Can you stack Epitalon with Low-Dose Naltrexone?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper